|
|
 |
|
Viewing report
|
|
|
|
Healthcare Review: Cancer - October 2002
Datamonitor, Feb 2002
The Cancer Review brings you the latest news, expert analysis and research in the oncology industry. It covers all the major current business issues and events, including R&D, licensing deals, alliances and joint ventures, and regulatory decisions.Strategic insight into the future shape of cancer companies and marketsThe most significant cancer industry news compiled into one monthly updateExpert analysis into the implications of the month's important cancer industry eventsInsight into the future shape of the market for players at all levelsAll the month's cancer stories in headline and summary formOut of the dozens of topics covered in this month's review, the most important include:* Novartis's Gleevec was granted a priority review by the FDA for possible use as a first-line treatment for newly diagnosed patients with Philadelphia-chromosome positive chronic myeloid leukemia in the chronic phase, the earliest stage of the disease.* A US District Court jury found unanimously in favor of Genentech following the claims of Chiron's that Genentech had infringed a patent with its metastatic breast cancer drug, Herceptin.Not only keeps you updated about industry events - it also gives you opinion and insightDraws upon Datamonitor analysts' extensive experience to bring you our perspective on the impact of the latest eventsProvides you with your own news archive to track company and industry progress, giving you an extensive reference to relevant events and issues
Customers who bought this item also bought
Prostate Cancer Opinion Leader Forum, 2002
Healthcare Review: Cancer - September 2002
Immunotherapy in Oncology: Gaining Momentum
The Asian Cancer Market Outlook to 2010
Cancer Therapeutics Markets
Drugs of Tomorrow 2002: Colorectal Cancer
Drugs of Tommorow 2002: Breast Cancer
The Eastern European Cancer Market Outlook to 2010
|
|
|
|
